Drug combo shows promise for tough head and neck cancers
NCT ID NCT03691714
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 study tested two drugs—durvalumab and cetuximab—together in 35 people with head and neck cancer that had come back or spread and was no longer responding to standard treatments. The goal was to see if the combination could shrink tumors. The study is complete, and results help guide future research.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
durvalumab and cetuximab
What this could lead to
If successful, this combination could offer a new treatment option for people with head and neck cancer that has returned or spread.
What could go wrong
This is a small, early-phase study (35 people) with no control group. The combination may cause serious side effects, and results may not apply to all patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEAD AND NECK CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
UC Health
Cincinnati, Ohio, 45219, United States